MedTrace Logo

Role of Metformin in Posterior Capsule Opacification

NCT07176338 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-09-16

No results posted yet for this study

Summary

Determination of concentrations of systemically applied metformin in human lens capsule and its ability to lower the proliferation rate of human lens epithelial cells in vitro.

Conditions

  • Cataract
  • Diabetes Mellitus Type 2

Interventions

DIAGNOSTIC_TEST

Blood and lens capsule samples for PK testing

Blood samples and lens capsule tissue will be collected from patients for PK testing

Sponsors & Collaborators

  • Vienna Institute for Research in Ocular Surgery

    lead OTHER

Principal Investigators

  • Oliver Findl, Prim. Prof. Dr. · Vienna Institute for Research in Ocular Surgery (VIROS)

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
105 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-12
Primary Completion
2025-10-01
Completion
2025-10-01

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07176338 on ClinicalTrials.gov